Claire Mazumdar, Chief Executive Officer at Bicara Therapeutics, sold BCAX on Jul 10, 2026
Data as of Oct 27
▼ SELL$283K9,972 shares at $28.42Claire Mazumdar Chief Executive OfficerBCAX Bicara Therapeutics Inc.
- Traded
- Jul 10, 2026
- Disclosed
- Jul 14, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
BCAX since disclosure
−37.8%
after the sale
Similar stocks (XLV) since disclosure
+13.2%
XLV — its sector index fund
Change in closing price from Jul 14, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLClaire Mazumdar Chief Executive OfficerBCAX Bicara Therapeutics Inc.$831disclosed Jul 14 · filed 4 days after the trade